James Fasano - IMS Health Director
Director
Mr. James A. Fasano is Director of IMS since January 2015. He is Managing Director responsible for leading CPP Investment Boards Funds Secondaries Coinvestments group and previously led CPPIBs Principal Investing group. Prior to joining CPPIB in 2004 Mr. Fasano worked in the Investment Banking group at Merrill Lynch Co. focusing on companies in the media and telecommunications sectors. Previously he was a member of the Mergers Acquisitions group at RBC Capital Markets and was a Commissioned Officer in the Canadian Armed Forces since 2015.
| Age | 45 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 203 448-4600 |
| Web | www.imshealth.com |
IMS Health Management Efficiency
The company has Return on Asset of 0.0554 % which means that on every $100 spent on assets, it made $0.0554 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.26 %, implying that it generated $0.26 on every 100 dollars invested. IMS Health's management efficiency ratios could be used to measure how well IMS Health manages its routine affairs as well as how well it operates its assets and liabilities.The company has 4.2 B in debt with debt to equity (D/E) ratio of 2.58, meaning that the company heavily relies on borrowing funds for operations. IMS Health Holdings has a current ratio of 1.1, demonstrating that it may not be capable to disburse its financial commitments when the payables are due. Debt can assist IMS Health until it has trouble settling it off, either with new capital or with free cash flow. So, IMS Health's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like IMS Health Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for IMS to invest in growth at high rates of return. When we think about IMS Health's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Barbara Gonda | Fomento Economico Mexicano | 60 | |
| Harold Taber | Monster Beverage Corp | 78 | |
| Louis Vachon | Molson Coors Brewing | 57 | |
| Jose Gracioso | Ambev SA ADR | 87 | |
| Paulina Marroquin | Fomento Economico Mexicano | 48 | |
| Armando Sada | Fomento Economico Mexicano | 61 | |
| Benjamin Polk | Monster Beverage Corp | 66 | |
| Nadia Shouraboura | Cimpress NV | 47 | |
| Zachary Sternberg | Cimpress NV | 32 | |
| Mark Hall | Monster Beverage Corp | 61 | |
| Roger Eaton | Molson Coors Brewing | 59 | |
| Russell Horowitz | Marchex | 57 | |
| Alvaro Souza | Ambev SA ADR | 67 | |
| Jose Rojas | Fomento Economico Mexicano | 66 | |
| Betty DeVita | Molson Coors Brewing | 57 | |
| Eva Fernandez | Fomento Economico Mexicano | 60 | |
| Alberto Gonzalez | Fomento Economico Mexicano | 88 | |
| Sanford Riley | Molson Coors Brewing | 64 | |
| Marcel Telles | Ambev SA ADR | 66 | |
| Roberto Motta | Ambev SA ADR | 63 | |
| Max Suberville | Fomento Economico Mexicano | 82 | |
Management Performance
| Return On Equity | 0.26 | |||
| Return On Asset | 0.0554 |
IMS Health Holdings Leadership Team
Elected by the shareholders, the IMS Health's board of directors comprises two types of representatives: IMS Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IMS. The board's role is to monitor IMS Health's management team and ensure that shareholders' interests are well served. IMS Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IMS Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ari Bousbib, Chairman, CEO and Pres | ||
| Michal Raczkowski, Member of the Supervisory Board | ||
| John Danhakl, Director | ||
| Wojciech Piwocki, Vice Chairman of the Management Board, Commercial Director | ||
| Jaroslaw Parczewski, Vice Chairman of the Supervisory Board | ||
| Satwinder Sian, Strategic Advisor To The CEO | ||
| Dariusz Lichacz, Vice Chairman of the Management Board, Music Director | ||
| Artur CzeszejkoSochacki, Secretary of the Supervisory Board | ||
| Giorgio Cirla, Non-Executive Independent Director | ||
| Jaroslaw Dominiak, Member of the Supervisory Board | ||
| Sharad Mansukani, Director | ||
| Andrzej Chajec, Independent Member of the Supervisory Board | ||
| James Fasano, Director | ||
| Ronald Bruehlman, CFO and Sr. VP | ||
| Bryan Taylor, Director | ||
| Karen Katen, Director | ||
| Andrea Paroli, Chief Administrative Officer, Director of Investor Relations, Financial Reporting Officer | ||
| Patrizia Pasquale, Independent Director | ||
| Michal Kornacki, Chairman of the Management Board | ||
| Wojciech Grendzinski, Vice Chairman of the Management Board, Director of Sales | ||
| Jose Fernandez, Sr. VP of Global Services | ||
| Todd Sisitsky, Director | ||
| Wieslaw Rozlucki, Chairman of the Supervisory Board | ||
| Harshan Bhangdia, Principal Accounting Officer, VP and Controller | ||
| Daniele Discepolo, Vice Chairman, Lead Independent Director | ||
| Maurizio Strozzi, Head of Internal Audit, CEO of Immsi Audit Scarl | ||
| Livio Corghi, Director | ||
| Robert Chu, Sr. VP of Technology Solutions | ||
| Roberto Colaninno, Chairman of the Board | ||
| Michele Colaninno, CEO, Executive Director, General Manager | ||
| Piotr Bielawski, Vice Chairman of the Management Board, CFO | ||
| Matteo Colaninno, Non-Executive Director | ||
| Harvey Ashman, Senior Vice President - External Affairs, General Counsel, Corporate Secretary | ||
| Ruggero Magnoni, Non-Executive Director | ||
| Giovanni Sala, Director | ||
| Ronald Rittenmeyer, Independent Director | ||
| Clinton Wolfe, Vice President - Human Resources | ||
| Rita Ciccone, Non-Executive Independent Director | ||
| Kevin Knightly, Sr. VP of Supply Management |
IMS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IMS Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | |||
| Return On Asset | 0.0554 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 17.32 % | |||
| Current Valuation | 12.23 B | |||
| Shares Outstanding | 331 M | |||
| Shares Owned By Insiders | 7.00 % | |||
| Shares Owned By Institutions | 94.00 % | |||
| Number Of Shares Shorted | 6.83 M | |||
| Price To Earning | 71.84 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in IMS Stock
If you are still planning to invest in IMS Health Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the IMS Health's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |